Ontology highlight
ABSTRACT:
SUBMITTER: Gryder BE
PROVIDER: S-EPMC3341130 | biostudies-literature | 2012 Mar
REPOSITORIES: biostudies-literature
Future medicinal chemistry 20120301 4
Histone deacetylase inhibitors (HDACis) have now emerged as a powerful new class of small-molecule therapeutics acting through the regulation of the acetylation states of histone proteins (a form of epigenetic modulation) and other non-histone protein targets. Over 490 clinical trials have been initiated in the last 10 years, culminating in the approval of two structurally distinct HDACis - SAHA (vorinostat, Zolinza™) and FK228 (romidepsin, Istodax™). However, the current HDACis have serious lim ...[more]